Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma

Current Allergy and Asthma Reports

Volumn 13, Issue 5, 2013, Pages 469-476

  Berair, Rachid ^a,b   Pavord, Ian D ^a  

^a GLENFIELD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Asthma; Eosinophils; IL 5; Inhibiting; Inhibition; Interleukin 5; Mepolizumab; Severe asthma; Treatment

Indexed keywords

BENRALIZUMAB; CORTICOSTEROID; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; MEPOLIZUMAB; PLACEBO; RESLIZUMAB;

ARTICLE; ASTHMA; ATOPIC DERMATITIS; CELL ACTIVATION; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHURG STRAUSS SYNDROME; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL; EOSINOPHILIC GASTROINTESTINAL DISORDER; HEMATOPOIESIS; HUMAN; HYPEREOSINOPHILIC SYNDROME; INNATE IMMUNITY; NONHUMAN; NOSE POLYP; PATHOGENESIS; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT ALLERGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ASTHMA; CLINICAL TRIALS AS TOPIC; EOSINOPHILS; HUMANS; INTERLEUKIN-5;

EID: 84885177716     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-013-0379-3     Document Type: Article

References (64)

1. British Thoracic Society Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax. 2008;4:iv1-121.
2. GINA Report: Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org (2012).
3. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet. 2006;368:780-93.
4. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31:143-78.
5. Bousquet J, Mantzouranis E, Cruz AA, Ait-Khaled N, Baena-Cagnani CE, Bleecker ER, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010;126:926-38.
6. Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol. 2011;128:1165-74.
7. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med. 1995;332:868-75.
8. Barnes PJ. Glucocorticoids and asthma. Ernst Schering Res Found Workshop. 2002;40:1-23.
9. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med. 2005;172:149-60.
10. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med. 2006;354:2689-95.
11. Bush A, Pavord ID. Omalizumab: NICE to USE you, to LOSE you NICE. Thorax. 2013;68:7-8.
12. Wenzel SE. Eosinophils in asthma - closing the loop or opening the door? N Engl J Med. 2009;360:1026-8.
13. Ehrlich P. Beiträge zur Kenntniss der granulirten Bindegewebszellen und der eosinophilen Leukocythen. Archiv fuer Anatomie und Physiologie: Physiologische Abteilung 1879: 166-169.
14. Weller PF. Human eosinophils. J Allergy Clin Immunol. 1997;100:283-7.
15. Rosenberg HF, Phipps S, Foster PS. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol. 2007;119:1303-10. quiz 1311-2.
16. Walsh ER, Stokes K, August A. The role of eosinophils in allergic airway inflammation. Discov Med. 2010;9:357-62.
17. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med. 1990;323:1033-9.
18. Motojima S, Frigas E, Loegering DA, Gleich GJ. Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. Am Rev Respir Dis. 1989;139:801-5.
19. Oddera S, Silvestri M, Balbo A, Jovovich BO, Penna R, Crimi E, et al. Airway eosinophilic inflammation, epithelial damage, and bronchial hyperresponsiveness in patients with mild-moderate, stable asthma. Allergy. 1996;51:100-7.
20. Hernnas J, Sarnstrand B, Lindroth P, Peterson CG, Venge P, Malmstrom A. Eosinophil cationic protein alters proteoglycan metabolism in human lung fibroblast cultures. Eur J Cell Biol. 1992;59:352-63.
21. Humbles AA, Lloyd CM, McMillan SJ, Friend DS, Xanthou G, McKenna EE, et al. A critical role for eosinophils in allergic airways remodeling. Science. 2004;305:1776-9.
22. Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160:1001-8.
23. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest. 2003;112:1029-36.
24. Coyle AJ, Ackerman SJ, Burch R, Proud D, Irvin CG. Human eosinophil-granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation. J Clin Invest. 1995;95:1735-40.
25. Lee JJ, Dimina D, Macias MP, Ochkur SI, McGarry MP, O'Neill KR, et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science. 2004;305:1773-6.
26. Wardlaw AJ, Dunnette S, Gleich GJ, Collins JV, Kay AB. Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity. Am Rev Respir Dis. 1988;137:62-9.
27. Wardlaw AJ, Brightling C, Green R, Woltmann G, Pavord I. Eosinophils in asthma and other allergic diseases. Br Med Bull. 2000;56:985-1003.
28. Deykin A, Lazarus SC, Fahy JV, Wechsler ME, Boushey HA, Chinchilli VM, et al. Asthma Clinical Research Network, National Heart, Lung, and Blood Institute/NIH. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol. 2005;115:720-7.
29. Leuppi JD, Salome CM, Jenkins CR, Anderson SD, Xuan W, Marks GB, et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med. 2001;163:406-12.
30. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360:1715-21.
31. Chlumsky J, Striz I, Terl M, Vondracek J. Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma. J Int Med Res. 2006;34:129-39.
32. Takatsu K. Interleukin-5 and IL-5 receptor in health and diseases. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87:463-85.
33. Sanderson CJ, O'Garra A, Warren DJ, Klaus GG. Eosinophil differentiation factor also has B-cell growth factor activity: proposed name interleukin 4. Proc Natl Acad Sci U S A. 1986;83:437-40.
34. van Leeuwen BH, Martinson ME, Webb GC, Young IG. Molecular organization of the cytokine gene cluster, involving the human IL-3, IL-4, IL-5, and GM-CSF genes, on human chromosome 5. Blood. 1989;73:1142-8.
35. Miyajima A, Mui AL, Ogorochi T, Sakamaki K. Receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3, and interleukin-5. Blood. 1993;82:1960-74.
36. Dent LA, Strath M, Mellor AL, Sanderson CJ. Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med. 1990;172:1425-31.
37. Fujisawa T, Abu-Ghazaleh R, Kita H, Sanderson CJ, Gleich GJ. Regulatory effect of cytokines on eosinophil degranulation. J Immunol. 1990;144:642-6.
38. Walsh GM, Hartnell A, Wardlaw AJ, Kurihara K, Sanderson CJ, Kay AB. IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CD11/18)-dependent manner. Immunology. 1990;71:258-65.
39. van Rensen EL, Stirling RG, Scheerens J, Staples K, Sterk PJ, Barnes PJ, et al. Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma. Thorax. 2001;56:935-40.
40. Shi H, Qin S, Huang G, Chen Y, Xiao C, Xu H, et al. Infiltration of eosinophils into the asthmatic airways caused by interleukin 5. Am J Respir Cell Mol Biol. 1997;16:220-4.
41. Rothenberg ME, Petersen J, Stevens RL, Silberstein DS, McKenzie DT, Austen KF, et al. IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity. J Immunol. 1989;143:2311-6.
42. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med. 1996;183:195-201.
43. Tanaka H, Komai M, Nagao K, Ishizaki M, Kajiwara D, Takatsu K, et al. Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice. Am J Respir Cell Mol Biol. 2004;31:62-8.
44. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356:2144-8.
45. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167:199-204.
46. Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al. International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176:1062-71.
47. Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A. Differences between asthma exacerbations and poor asthma control. Lancet. 1999;353:364-9.
48. Pauwels RA, Löfdahl C, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma. N Engl J Med. 1997;337:1405-11.
49. Jayaram L, Pizzichini MM, Cook RJ, Boulet LP, Lemiere C, Pizzichini E, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J. 2006;27:483-94.
50. Green RH, Brightling CE, McKenna S, Hargadon B, Neale N, Parker D, et al. Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. Eur Respir J. 2006;27:1144-51.
51. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985-93.
52. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973-84.
53. •• Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651-9. This large multicenter RCT showed clear effect of mepolizumab on severe exacerbation frequency in severe eosinophilic asthmatics.
54. • Liu Y, Zhang S, Li DW, Jiang SJ. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS One. 2013;8:e59872. A recent large meta-analysis summarising RCT on the use of mepolizumab in asthmatics.
55. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184:1125-32.
56. Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol. 2010;125:1237-1244.e2.
57. Ghazi A, Trikha A, Calhoun WJ. Benralizumab - a humanized mAb to IL-5Ralpha with enhanced antibody-dependent cell-mediated cytotoxicity - a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012;12:113-8.
58. Allakhverdi Z, Allam M, Renzi PM. Inhibition of antigen-induced eosinophilia and airway hyperresponsiveness by antisense oligonucleotides directed against the common beta chain of IL-3, IL-5, GM-CSF receptors in a rat model of allergic asthma. Am J Respir Crit Care Med. 2002;165:1015-21.
59. Gauvreau GM, Boulet LP, Cockcroft DW, Baatjes A, Cote J, Deschesnes F, et al. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med. 2008;177:952-8.
60. Huang H, Lee C, Chiang B. Small interfering RNA against interleukin-5 decreases airway eosinophilia and hyper-responsiveness. Gene Ther. 2008;15:660-7.
61. Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, et al. Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358:1215-28.
62. Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1:39-47.
63. Bafadhel M, Saha S, Siva R, McCormick M, Monteiro W, Rugman P, et al. Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD. Respiration. 2009;78:256-62.
64. Abba AA. Exhaled nitric oxide in diagnosis and management of respiratory diseases. Ann Thorac Med. 2009;4:173-81.